[EN] HETEROCYCLIC CONSTRAINED TRICYCLIC SULFONAMIDES AS ANTI-CANCER AGENTS<br/>[FR] SULFONAMIDES HÉTÉROCYCLIQUES TRICYCLIQUES CONTRAINTS EN TANT QU'AGENTS ANTI-CANCÉREUX
申请人:ICAHN SCHOOL MED MOUNT SINAI
公开号:WO2017044569A1
公开(公告)日:2017-03-16
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a therapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed..